Results 31 to 40 of about 21,080,479 (286)
Complications after CD19+ CAR T-Cell Therapy [PDF]
, 2020 Clinical trials demonstrated that CD19+ chimeric antigen receptor (CAR) T-cells can be highly effective against a number of malignancies. However, the complete risk profile of CAR T-cells could not be defined in the initial trials.
Penack, Olaf +3 more
core +1 more source
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Frontiers in Immunology, 2023 Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies.
Zixin Lv +5 more
doaj +1 more source
Current state of CAR-T therapy for T-cell malignancies
, 2022 Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/
Liangkui Luo +13 more
core +1 more source
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed
Manasi P. Jogalekar +7 more
doaj +1 more source
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy ...
Robert C. Sterner, Rosalie M. Sterner
doaj +1 more source
, 2023 Tingyu Liang,* Yixuan Song,* Lingui Gu, Yu Wang, Wenbin Ma Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China*These ...
Liang T, Gu L, Wang Y, Song Y, Ma W
core
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
, 2022 CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T ...
Christian Martin Seitz +11 more
core +1 more source
Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
eJHaem, 2022 In recent years, we have seen rapid expansion of chimeric antigen receptor T‐cell (CAR‐T) therapies in multiple malignancies. CAR‐T therapy has profoundly altered the treatment landscape of non‐Hodgkin lymphoma, B‐cell acute lymphoblastic leukemia, and ...
Salyka Sengsayadeth +3 more
doaj +1 more source
Evaluation of Toxicity Associated with CAR-T Cell Therapy and Nursing Interventions [PDF]
Objective: Chimeric antigen receptor (CAR)-T cell therapy is a new immunotherapy approach that has started to been used in recent years and is developing rapidly.
Gülbeyaz CAN +7 more
core +1 more source
Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer
Advanced Science, 2020 Growing experience with engineered chimeric antigen receptor (CAR)‐T cells has revealed some of the challenges associated with developing patient‐specific therapy.
Ahmed M. E. Abdalla +7 more
doaj +1 more source